Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial

Circulation

Volumn 126, Issue 20, 2012, Pages 2408-2417

  Raal, Frederick ^a,c   Scott, Rob ^b   Somaratne, Ransi ^b   Bridges, Ian ^c   Li, Gang ^d   Wasserman, Scott M ^b   Stein, Evan A ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Metabolic and Atherosclerotic Research Center   (United States)

Author keywords

familial hypercholesterolemia; low density lipoprotein cholesterol; proprotein convertase subtilisin kexin type 9; randomized controlled trial

Indexed keywords

AMG 145; ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; KEXIN 9; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PLACEBO; ROSUVASTATIN; SIMVASTATIN; SUBTILISIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEADACHE; HETEROZYGOTE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN BURNING SENSATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84869220345     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.144055     Document Type: Article

References (27)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease. 2001:2863-2913.
2. Slack J. Risks of ischaemic heart-disease in familial hyperlipopro-teinaemic states. Lancet. 1969;2:1380-1382.
3. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008; 72:485-498. (Pubitemid 351850090)
4. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987;84:6919-6923. (Pubitemid 18025501)
5. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholes-terolemia. Nat Genet. 2003;34:154-156. (Pubitemid 36666925)
6. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholester-olaemia: a prospective registry study. Eur Heart J. 2008;29:2625-2633.
7. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol. 2011;108:223-226.
8. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
9. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189-194.
10. Stein EA, Ose L, Retterstol K, Tonstad S, Schleman M, Harris S, Sager P. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol. 2007;1:280-286. (Pubitemid 47364514)
11. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50 Suppl:S172-S177.
12. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
13. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein con-vertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable ator-vastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
14. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
15. Dias C, Shaywitz A, Wasserman SM, Smith B, Gao B, Stolman D, Crispino C, Smirnakis K, Emery M, Colbert A, Gibbs J, Retter M, Cooke B, Uy S, Matson M, Stein E. Effects of AMG 145 on LDL-C Levels: results from two randomized, double-blind, placebo-controlled, ascending-dose phase I studies in healthy volunteers and hypercholester-olemic subjects on statins. J Am Coll Cardiol. 2012 [in press].
16. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholester-olaemia. BMJ. 1991;303:893-896.
17. Rabinovitch A. The College of American Pathologists laboratory accreditation program. Accred Qual Assur. 2002;7:473-476. (Pubitemid 36165310)
18. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135. (Pubitemid 19070302)
19. Warnick GR, Benderson JM, Albers JJ. Interlaboratory proficiency survey of high-density lipoprotein cholesterol measurement. Clin Chem. 1983;29:516-519. (Pubitemid 13160764)
20. Lipid research clinics. Manual of laboratory operations. Lipid and lipo-protein analysis (revised). Department of Health and Human Services publication No. (NIH) 75-67815. 1982.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Dati F, Tate JR, Marcovina SM, Steinmetz A. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay-Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42:670-676. (Pubitemid 38979146)
23. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497-505.
24. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413-1419.
25. Scharnagl H, Nauck M, Wieland H, Marz W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med. 2001;39:426-431. (Pubitemid 32529925)
26. Turner T, Plunkett N, Miller J, Fearn J, Stein EA. Validity of calculated LDL cholesterol by the Friedewald formula compared to LDL cholesterol measured by ultracentrifugation in patients with very low LDL. http://www.aacc.org/ events/annualmtgdirectory/Documents/AACC-12-Abstracts-A77-A119.pdf. 2012:Abstract A105.
27. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.